Related Experiment Video

Updated: Feb 17, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.9K

A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity

Wentong Deng1,2, Jiayu Liu1,2, Haitao Pan1,2

  • 1School of Pharmaceutical Sciences.

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|December 13, 2017
PubMed

Insights

A novel bispecific antibody, Her2(Per)-S-Fab, effectively targets and reduces HER2-positive breast cancer tumors. This antibody demonstrates potent cytotoxicity, offering a promising new treatment alternative for patients with HER2-positive cancers.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Human epidermal growth factor receptor 2 (HER2) overexpression drives metastatic breast cancer progression.
  • Monoclonal antibodies like trastuzumab and pertuzumab are established HER2-targeted therapies, inhibiting HER2 signaling and mediating antibody-dependent cell-mediated cytotoxicity (ADCC).

Purpose of the Study:

  • To develop and evaluate a novel bispecific antibody, Her2(Per)-S-Fab, for enhanced HER2-positive cancer treatment.
  • To assess the efficacy of Her2(Per)-S-Fab in inhibiting tumor growth and mediating cytotoxicity.

Main Methods:

  • Generation of a bispecific antibody (Her2(Per)-S-Fab) by conjugating a pertuzumab fragment (Fab) to an anti-CD16 single domain antibody.
  • Efficient expression and purification of Her2(Per)-S-Fab using Escherichia coli.
  • In vitro and in vivo studies to evaluate the cytotoxic effects of Her2(Per)-S-Fab against HER2-positive tumor cells.

Main Results:

  • Her2(Per)-S-Fab was successfully expressed and purified from E. coli.
  • Demonstrated potent in vitro and in vivo cytotoxicity against HER2-positive tumor cells.
  • Indicated potential for enhanced anti-tumor activity compared to existing therapies.

Conclusions:

  • Her2(Per)-S-Fab is a viable bispecific antibody candidate for targeting HER2-positive cancers.
  • This novel antibody demonstrates significant anti-tumor efficacy, presenting a potential new therapeutic option.
  • Further investigation into Her2(Per)-S-Fab could lead to improved treatment strategies for HER2-positive breast cancer patients.

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.3K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K